Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant camrelizumab after concurrent chemoradiotherapy in high-risk locally advanced cervical cancer
ChiCTR2500102676Phase 4Completed
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- May 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of camrelizumab in Cervical Cancer (CC) (2 arms), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoint: Progression-free survival. Started May 2025; status: completed.
02
Drugs
camrelizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2500102676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102676.